From this analysis, possession of at least one or more variant GSTM3 rs11102001 was associated with increased PCa risk among subjects in the highest percentile of DiMeIQx intake compared to subjects in the lowest percentile [OR (95%CI) = 2.3 (1.2–4.7). Here, GSTM3 is linked to posterior cortical atrophy.